AstraZeneca Collaboration
Undisclosed
ResearchActive
Key Facts
About Nanexa
Nanexa is a clinical-stage biotech company on a mission to redefine injectable medicines through its unique nanoengineering platform, PharmaShell®. The company has achieved significant validation through strategic partnerships with industry leaders like Novo Nordisk and AstraZeneca and is progressing proprietary assets toward clinical proof-of-concept. Its dual business model combines internal pipeline development with high-value technology licensing, aiming to capture value in the expansive long-acting injectables market.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |